← Back to Search

Alkylating agents

Chemotherapy Combination for Non-Hodgkin's Lymphoma

Phase 2
Waitlist Available
Research Sponsored by Theradex
Eligibility Criteria Checklist
Specific guidelines that determine who can or cannot participate in a clinical trial
Must have
No more than 1 episode of progressive disease occurring after a response to prior chemotherapy
Renal: Creatinine no greater than 1.5 mg/dL
Timeline
Screening 3 weeks
Treatment Varies
Follow Up up to 5 years
Awards & highlights

Study Summary

This trial is studying how well giving pixantrone together with cytarabine, methylprednisolone, and cisplatin works in treating patients with relapsed aggressive non-Hodgkin's lymphoma.

Who is the study for?
This trial is for adults with aggressive non-Hodgkin's lymphoma that has returned after treatment. Eligible patients have certain subtypes of this cancer, measurable lesions (except those with bone marrow as the only site), and a history of responding to chemotherapy. They must not be pregnant or nursing, should use effective contraception, and cannot have severe organ damage or infections.Check my eligibility
What is being tested?
The study tests a combination of chemotherapy drugs: pixantrone, cytarabine, methylprednisolone, and cisplatin in patients whose aggressive non-Hodgkin's lymphoma has relapsed. The goal is to see if this mix can effectively kill more cancer cells than previous treatments.See study design
What are the potential side effects?
Potential side effects include damage to organs such as the heart and kidneys, blood cell count issues leading to increased infection risk or bleeding problems, nerve damage which could cause numbness or pain, fatigue from anemia due to low red blood cell counts, nausea from stomach lining irritation.

Eligibility Criteria

Inclusion Criteria

You may be eligible if you check “Yes” for the criteria below
Select...
My cancer worsened only once after responding to chemotherapy.
Select...
My creatinine level is 1.5 mg/dL or lower.
Select...
My liver function tests are within the required limits.
Select...
I am fully active or able to carry out light work.
Select...
My lymphoma is aggressive and confirmed by a biopsy.
Select...
I am 18 years old or older.
Select...
My heart functions well, with no recent heart attacks or severe irregular heartbeats.

Timeline

Screening ~ 3 weeks
Treatment ~ Varies
Follow Up ~up to 5 years
This trial's timeline: 3 weeks for screening, Varies for treatment, and up to 5 years for reporting.

Treatment Details

Find a Location

Who is running the clinical trial?

TheradexLead Sponsor
33 Previous Clinical Trials
1,532 Total Patients Enrolled
3 Trials studying Lymphoma
80 Patients Enrolled for Lymphoma
Julie M. Vose, MDStudy ChairUniversity of Nebraska
12 Previous Clinical Trials
1,921 Total Patients Enrolled
12 Trials studying Lymphoma
1,921 Patients Enrolled for Lymphoma

Media Library

Cisplatin (Alkylating agents) Clinical Trial Eligibility Overview. Trial Name: NCT00069966 — Phase 2
Lymphoma Research Study Groups:
Lymphoma Clinical Trial 2023: Cisplatin Highlights & Side Effects. Trial Name: NCT00069966 — Phase 2
Cisplatin (Alkylating agents) 2023 Treatment Timeline for Medical Study. Trial Name: NCT00069966 — Phase 2

Frequently Asked Questions

These questions and answers are submitted by anonymous patients, and have not been verified by our internal team.

With how many medical clinics is this research being conducted?

"There are 28 sites for this clinical trial, which are situated in Newark, Duarte, Denver and other cities. To limit travel as a participant, it is best to choose the location nearest you."

Answered by AI

Are patients being currently enrolled in this trial?

"The clinical trial documented on clinicaltrials.gov is not recruiting patients at this time. This particular study was first advertised on April 1st, 2003 and underwent its most recent update on July 4th, 2009. There are 1791 other active clinical trials that are looking for participants right now."

Answered by AI

Is there a considerable risk involved with this treatment?

"This treatment received a safety score of 2 because, while there is some evidence backing its safety, there is no data to support efficacy."

Answered by AI
~16 spots leftby Mar 2025